- Home
- INTR vs TFX Comparison
INTR vs TFX Comparison
Compare INTR & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | TFX |
|---|---|---|
| Founded | 1994 | 1943 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.6B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | INTR | TFX |
|---|---|---|
| Price | $8.40 | $126.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.00 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 3.3M | 659.6K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.35% | 1.09% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $84.64 | $15.97 |
| Revenue Next Year | $18.25 | $5.15 |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.62 | $100.18 |
| 52 Week High | $10.36 | $138.93 |
Technical Indicators
Market Signals| Indicator | INTR | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 68.97 |
| Support Level | $7.81 | $123.80 |
| Resistance Level | $8.64 | $130.56 |
| Average True Range (ATR) | 0.36 | 3.24 |
| MACD | 0.08 | 1.21 |
| Stochastic Oscillator | 77.99 | 96.16 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.